TY - JOUR
T1 - Tamsulosin in urology
T2 - beyond benign prostatic hyperplasia
AU - Laxman Prabhu, G. G.
AU - Prajapati, Hiren
AU - Chaturvedi, Alok
AU - Dave, Nilanj
AU - Jain, Amit B.
PY - 2019/4/10
Y1 - 2019/4/10
N2 -
Tamsulosin, a third-generation uroselective α
1A
adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.
AB -
Tamsulosin, a third-generation uroselective α
1A
adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.
UR - http://www.scopus.com/inward/record.url?scp=85062948883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062948883&partnerID=8YFLogxK
U2 - 10.1007/s40267-019-00611-1
DO - 10.1007/s40267-019-00611-1
M3 - Review article
AN - SCOPUS:85062948883
SN - 1172-0360
VL - 35
SP - 181
EP - 184
JO - Drugs and Therapy Perspectives
JF - Drugs and Therapy Perspectives
IS - 4
ER -